Survival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastoma

被引:76
|
作者
Sun, Matthew Z. [1 ]
Oh, Taemin [2 ]
Ivan, Michael E. [1 ]
Clark, Aaron J. [1 ]
Safaee, Michael [1 ]
Sayegh, Eli T. [2 ]
Kaur, Gurvinder [2 ]
Parsa, Andrew T. [2 ]
Bloch, Orin [2 ]
机构
[1] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA
[2] Northwestern Univ, Dept Neurol Surg, Feinberg Sch Med, Chicago, IL 60611 USA
关键词
glioblastoma; overall survival; progression-free survival; treatment delay; The Cancer Genome Atlas; oncology; ADJUVANT TEMOZOLOMIDE; WAITING-TIMES; RADIOTHERAPY; DELAY; CONCOMITANT; RADIATION; EORTC;
D O I
10.3171/2014.9.JNS14193
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
OBJECT There are few and conflicting reports on the effects of delayed initiation of chemoradiotherapy on the survival of patients with glioblastoma. The standard of care for newly diagnosed glioblastoma is concurrent radiotherapy and temozolomide chemotherapy after maximal safe resection; however, the optimal timing of such therapy is poorly defined. Given the lack of consensus in the literature, the authors performed a retrospective analysis of The Cancer Genome Atlas (TCGA) database to investigate the effect of time from surgery to initiation of therapy on survival in newly diagnosed glioblastoma. METHODS Patients with primary glioblastoma diagnosed since 2005 and treated according to the standard of care were identified from TCGA database. Kaplan-Meier and multivariate Cox regression analyses were used to compare overall survival (OS) and progression-free survival (PFS) between groups stratified by postoperative delay to initiation of radiation treatment. RESULTS There were 218 patients with newly diagnosed glioblastoma with known time to initiation of radiotherapy identified in the database. The median duration until therapy was 27 days. Delay to radiotherapy longer than the median was not associated with worse PFS (HR = 0.918, p = 0.680) or OS (HR = 1.135, p = 0.595) in multivariate analysis when controlling for age, sex, KPS score, and adjuvant chemotherapy. Patients in the highest and lowest quartiles for delay to therapy (<= 20 days vs >= 36 days) did not statistically differ in PFS (p = 0.667) or OS (p = 0.124). The small subset of patients with particularly long delays (>42 days) demonstrated worse OS (HR = 1.835, p = 0.019), but not PFS (p = 0.74). CONCLUSIONS Modest delay in initiation of postoperative chemotherapy and radiation does not appear to be associated with worse PFS or OS in patients with newly diagnosed glioblastoma, while significant delay longer than 6 weeks may be associated with worse OS.
引用
收藏
页码:1144 / 1150
页数:7
相关论文
共 50 条
  • [1] Impact of time to initiation of radiotherapy on survival after resection of newly diagnosed glioblastoma
    Sotirios Katsigiannis
    Boris Krischek
    Stefanie Barleanu
    Stefan Grau
    Norbert Galldiks
    Marco Timmer
    Christoph Kabbasch
    Roland Goldbrunner
    Pantelis Stavrinou
    Radiation Oncology, 14
  • [2] Impact of time to initiation of radiotherapy on survival after resection of newly diagnosed glioblastoma
    Katsigiannis, Sotirios
    Krischek, Boris
    Barleanu, Stefanie
    Grau, Stefan
    Galldiks, Norbert
    Timmer, Marco
    Kabbasch, Christoph
    Goldbrunner, Roland
    Stavrinou, Pantelis
    RADIATION ONCOLOGY, 2019, 14 (1)
  • [3] Delaying standard combined chemoradiotherapy after surgical resection does not impact survival in newly diagnosed glioblastoma patients
    Louvel, Guillaume
    Metellus, Philippe
    Noel, Georges
    Peeters, Sophie
    Guyotat, Jacques
    Duntze, Julien
    Le Reste, Pierre-Jean
    Phong Dam Hieu
    Faillot, Thierry
    Litre, Fabien
    Desse, Nicolas
    Petit, Antoine
    Emery, Evelyne
    Voirin, Jimmy
    Peltier, Johann
    Caire, Francois
    Vignes, Jean-Rodolphe
    Barat, Jean-Luc
    Langlois, Olivier
    Menei, Philippe
    Dumont, Sarah N.
    Zanello, Marc
    Dezamis, Edouard
    Dhermain, Frederic
    Pallud, Johan
    RADIOTHERAPY AND ONCOLOGY, 2016, 118 (01) : 9 - 15
  • [4] Survival impact of delaying postoperative chemoradiotherapy in newly-diagnosed glioblastoma patients
    Zhang, Maochen
    Xu, Fei
    Ni, Weiqiong
    Qi, Weixiang
    Cao, Weiguo
    Xu, Cheng
    Chen, Jiayi
    Gao, Yunsheng
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (09) : 5450 - 5458
  • [5] Impact of Delay in Initiation of Radiation Therapy in Newly Diagnosed Glioblastoma Patients after Gross Total Resection
    Tabrizi, S.
    Rahman, R.
    Cagney, D. N.
    Aizer, A. A.
    Tanguturi, S.
    Arvold, N. D.
    Reardon, D. A.
    Lee, E. Q.
    Nayak, L.
    Rinne, M.
    Ligon, K. L.
    Wen, P.
    Alexander, B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E110 - E111
  • [6] The impact of the time to start radiation therapy on overall survival in newly diagnosed glioblastoma
    Vanessa Montes Santos
    Gustavo Nader Marta
    Marcella Coelho Mesquita
    Rossana Veronica Mendoza Lopez
    Edla Renata Cavalcante
    Olavo Feher
    Journal of Neuro-Oncology, 2019, 143 : 95 - 100
  • [7] The impact of the time to start radiation therapy on overall survival in newly diagnosed glioblastoma
    Santos, Vanessa Montes
    Marta, Gustavo Nader
    Mesquita, Marcella Coelho
    Mendoza Lopez, Rossana Veronica
    Cavalcante, Edla Renata
    Feher, Olavo
    JOURNAL OF NEURO-ONCOLOGY, 2019, 143 (01) : 95 - 100
  • [8] The impact of timing of temozolomide chemoradiotherapy for newly diagnosed glioblastoma on patient overall survival: A multicenter retrospective study
    Lau, Arthur C. K.
    Chan, Brandon L. H.
    Yeung, Carly S. K.
    Li, Lai-Fung
    Chan, Danny T. M.
    Lee, Michael W. Y.
    Chan, Tony K. T.
    Ho, Jason M. K.
    Cheung, Ka-Man
    Tse, Teresa P. K.
    Lau, Sarah S. N.
    Chow, Joyce S. W.
    Ko, Natalie M. W.
    Loong, Herbert H. F.
    El-Helali, Aya
    Poon, Wai-Sang
    Woo, Peter Y. M.
    NEURO-ONCOLOGY ADVANCES, 2024, 6 (01)
  • [9] The timing of chemoradiotherapy after surgical resection and its impact on overall survival in glioblastoma.
    Press, Robert H.
    Shafer, Sarah L.
    Jiang, Renjian
    Buchwald, Zachary S.
    Abugideiri, Mustafa
    Tian, Sibo
    Morgan, Tiffany
    Behera, Madhusmita
    Sengupta, Soma
    Voloschin, Alfredo Daniel
    Olson, Jeffrey J.
    Curran, Walter John, Jr.
    Eaton, Bree Ruppert
    Shu, Hui-Kuo George
    Zhong, Jim
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] CHEMORADIOTHERAPY OF NEWLY DIAGNOSED GLIOBLASTOMA WITH INTENSIFIED TEMOZOLOMIDE
    Weiler, Markus
    Hartmann, Christian
    Wiewrodt, Dorothee
    Herrlinger, Ulrich
    Gorlia, Thierry
    Baehr, Oliver
    Meyermann, Richard
    Bamberg, Michael
    Tatagiba, Marcos
    von Deimling, Andreas
    Weller, Michael
    Wick, Wolfgang
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 77 (03): : 670 - 676